---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-035733"
form_type: "8-K"
ticker: null
cik: "0000793171"
company_name: "Vitro Biopharma, Inc."
filed_at: "2022-12-16T23:59:59+00:00"
generated_at: "2026-06-21T03:48:31.369863+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Vitro Biopharma to restate Q3/Q1 FY2022 financials due to revenue recognition error; net loss increases $22.9k

## Summary
- Restating unaudited interim statements for three and nine months ended July 31, 2022 under ASC 606.
- Revenue to decrease by $200,000; G&A expenses to decrease by $177,147; net loss to increase by $22,853.
- Error stems from contract with European Wellness Biomedical Group and its subsidiary BioPep.
- Material weakness identified in internal control over revenue recognition as of July 31, 2022.
- Company expects to file amended Form 10-12G with restated financial statements.

## SEC filing metadata
- accession: 0001493152-22-035733
- form_type: 8-K
- cik: 0000793171
- company_name: Vitro Biopharma, Inc.
- filed_at: 2022-12-16T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 4.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/793171/000149315222035733/0001493152-22-035733-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/793171/000149315222035733/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-035733
- JSON: https://secwatch.observer/filing/0001493152-22-035733.json
- Plain text: https://secwatch.observer/filing/0001493152-22-035733.txt

## Key facts
- Auditor Changes
  Vitro Biopharma, Inc. reported that prior financial statements should not be relied upon.
  - Action: non reliance
  source text: the Company’s previously issued unaudited interim consolidated financial statements for the Restated Periods included in its Form 10-12G/A, as originally filed with the Securities and Exchange Commission (“SEC”) on November 4, 2022, should no longer be relied upon.
  evidence_url: https://www.sec.gov/Archives/edgar/data/793171/000149315222035733/0001493152-22-035733-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.